MEDIPOST has achieved 50 local and global patent registrations.

This is an extraordinary achievement, rarely seen in bio venture companies, and is a fruition of effort MEDIPOST has put into core technology development, investing more than 30% of its yearly sales into research and development since its foundation in 2000.

By categories, the majority (26 patents) of patents was related to CNS diseases such as Alzheimer’s disease and stroke and 9 patents were registered in arthritis.

There were 6 patents related to cord blood bank, 4 patents related to stem cell culture method, 3 patents related to lung diseases and 2 patents related to cord blood stem cell transplantation.

More patents (29 patents) were in foreign countries such as US, Europe, Japan, China, Singapore and Australia, compared to 21 patents registered in Korea.

Also, MEDIPOST has applied 152 patents locally and globally so far.